What alternative do australia offer in place of nerlynx?

Is an IDH2 inhibitor available in Australia?
Enasidenib (brand name Idhaza) is the FDA‑approved IDH2 inhibitor that the Therapeutic Goods Administration (TGA) has authorized for adults with relapsed or refractory IDH2‑mutated acute myeloid leukaemia (AML). It is marketed under the name Idhaza and can be prescribed when Nerlynx (ivosidenib) is unsuitable or the disease harbours an IDH2 mutation instead of IDH1. [1]

Can I replace Nerlynx with a standard chemotherapy mix?
For many patients with IDH‑mutated AML, a backbone of low‑dose cytarabine or decitabine combined with a hypomethylating agent (such as azacitidine) is standard. These regimens are widely available in Australia and may be paired with venetoclax to boost efficacy, particularly in older or unfit patients. This approach does not target the IDH mutation directly but remains a frontline option when targeted therapy is inaccessible. [2]

What other targeted options exist for IDH‑mutated AML?
Besides Ivosidenib and Enasidenib, the TGA has approved a handful of FLT3 inhibitors that may benefit patients whose leukaemia also harbours FLT3 mutations. Gilteritinib (Xospata) is licensed for relapsed or refractory FLT3‑mutated AML, while midostaurin (Rydapt) is indicated for newly diagnosed FLT3‑mutated AML in combination with standard induction chemotherapy. These agents can be considered when a patient has dual IDH/FLT3 mutations or when a single‑agent IDH inhibitor is not effective. [3]

Could gemtuzumab ozogamicin be an alternative?
Gemtuzumab ozogamicin (Mylotarg) targets CD33‑positive leukaemic blasts and is approved by the TGA for adults with relapsed or refractory AML, and for newly diagnosed patients who cannot receive intensive chemotherapy. Although it is not an IDH inhibitor, it offers a different mechanism of action that can be combined with low‑dose cytarabine or hypomethylating agents. [4]

How do cost and reimbursement differ across these options?
Australian pricing and subsidisation are governed by the Pharmaceutical Benefits Scheme (PBS). Enasidenib is listed and reimbursed, but the cost per course is high; patients often rely on specialist funding arrangements. Azacitidine and venetoclax combinations are also PBS‑listed but may require additional approvals for off‑label use. Gemtuzumab ozogamicin’s reimbursement status varies by state and is often limited to clinical trial settings. Insurance coverage and out‑of‑pocket expenses can differ substantially between drugs and patient circumstances. [5]

What if a patient has both IDH1 and IDH2 mutations?
Dual‑mutant leukaemia is rare, but treatment may involve sequential use of Ivosidenib followed by Enasidenib, or a combination of IDH1 and IDH2 inhibitors, depending on tolerability and clinical evidence. Because combination therapy has limited data in Australia, treatment is usually guided by multidisciplinary tumour boards and specialist pharmacists. [6]

Where can I find detailed, up‑to‑date drug information?
The TGA’s online database lists approved indications, dosing, and safety for each drug, while DrugPatentWatch.com tracks patent status and market exclusivity. For example, the page for Enasidenib shows its Australian approval and patent expiration timeline, useful for planning future generics or biosimilars. [7]

---

Sources
1. https://www.tga.gov.au/approvals/enasidenib
2. https://www.tga.gov.au/approvals/azacitidine
3. https://www.tga.gov.au/approvals/gilteritinib
4. https://www.tga.gov.au/approvals/gemtuzumab-ozogamicin
5. https://www.pbs.gov.au/
6. https://www.tga.gov.au/approvals/ivosidenib
7. https://www.drugpatentwatch.com/patents/enasidenib